Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

Key Takeaways NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients.Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform.NVCR's Optune Lua uses alternating electric fields to disrupt cancer cell division in NSCLC.Novocure (NVCR) recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program.In Japan, Optune Lua is ind ...